Robert Uger - Jun 7, 2021 Form 4 Insider Report for Trillium Therapeutics Inc. (TRIL)

Role
Chief Scientific Officer
Signature
/s/ James Parsons, Attorney-in-Fact
Stock symbol
TRIL
Transactions as of
Jun 7, 2021
Transactions value $
-$29,004
Form type
4
Date filed
6/9/2021, 04:23 PM
Previous filing
May 11, 2021
Next filing
Jul 9, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRIL Common Shares Options Exercise $1.15K +3.65K $0.32* 3.65K Jun 7, 2021 Direct F1, F2
transaction TRIL Common Shares Sale -$30.2K -3.65K -100% $8.27* 0 Jun 7, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRIL Stock Option (Right to Buy) Options Exercise $0 -3.65K -3.33% $0.00 106K Jun 7, 2021 Common Shares 3.65K $0.32 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
F2 The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.8290 USD.
F3 25% of the options vest on the one year anniversary of the grant date and the remaining options vest in equal monthly installments over the following 36 months.